Table 6.
Aggregate life-years and QALYs lost to pancreatic cancer across Europe (EU 28)
| Incident casesa | Aggregate life-years lost | Aggregate QALYs lost | |
|---|---|---|---|
| All pancreatic cancer | |||
| Globocan (crude) | 79,331 | 1,167,488 | 914,594 |
| Systematic review (crude) | 62,203 | 915,428 | 717,134 |
| Systematic review (ESP) | 52,872 | 778,095 | 609,549 |
| Metastatic pancreatic cancer | |||
| Globocan (crude) | 44,901 | 663,792 | 519,606 |
| Systematic review (crude) | 35,207 | 520,479 | 407,423 |
| Systematic review (ESP) | 29,925 | 442,397 | 346,301 |
ESP age adjusted with European Standard Population
aMetastatic incident cases based on 62.5 % of patients in Stages IV, a figure scaled up from that in the original publication in order that proportions of patients in the study in Stages I to IV sum to 100 % [15]